Show simple item record

dc.contributor.authorSmit, E
dc.contributor.authorSocinski, M
dc.contributor.authorMullaney, B
dc.contributor.authorMyrand, S
dc.contributor.authorScagliotti, G
dc.contributor.authorLorigan, Paul C
dc.contributor.authorReck, M
dc.contributor.authorCiuleanu, T
dc.contributor.authorVon Pawel, J
dc.contributor.authorKaraseva, N
dc.contributor.authorSzczesna, A
dc.contributor.authorOhannesian, D
dc.contributor.authorPowell, E
dc.contributor.authorHozak, R
dc.contributor.authorHong, S
dc.contributor.authorGuba, S
dc.contributor.authorThatcher, Nick
dc.date.accessioned2012-11-12T16:32:01Z
dc.date.available2012-11-12T16:32:01Z
dc.date.issued2012-07
dc.identifier.citationBiomarker analysis in a phase III study of pemetrexed-carboplatin versus etoposide-carboplatin in chemonaive patients with extensive-stage small-cell lung cancer. 2012, 23 (7):1723-9 Ann Oncolen_GB
dc.identifier.issn1569-8041
dc.identifier.pmid22186609
dc.identifier.doi10.1093/annonc/mdr563
dc.identifier.urihttp://hdl.handle.net/10541/251876
dc.description.abstractClinical results of a randomized phase III trial comparing pemetrexed-carboplatin (PC) with etoposide-carboplatin (EC) in chemonaive patients with extensive-stage disease small-cell lung cancer (ED-SCLC) resulted in trial closure for futility; biomarker analyses using immunohistochemistry (IHC) and single-nucleotide polymorphisms (SNPs) are described herein.
dc.language.isoenen
dc.rightsArchived with thanks to Annals of oncology : official journal of the European Society for Medical Oncology / ESMOen_GB
dc.titleBiomarker analysis in a phase III study of pemetrexed-carboplatin versus etoposide-carboplatin in chemonaive patients with extensive-stage small-cell lung cancer.en
dc.typeArticleen
dc.contributor.departmentDepartment of Pulmonary Diseases, Vrije University Medical Center, Amsterdam, The Netherlands.en_GB
dc.identifier.journalAnnals of Oncologyen_GB
html.description.abstractClinical results of a randomized phase III trial comparing pemetrexed-carboplatin (PC) with etoposide-carboplatin (EC) in chemonaive patients with extensive-stage disease small-cell lung cancer (ED-SCLC) resulted in trial closure for futility; biomarker analyses using immunohistochemistry (IHC) and single-nucleotide polymorphisms (SNPs) are described herein.


This item appears in the following Collection(s)

Show simple item record